Pharmaceutical Giant Settles Legal Dispute with Telehealth Company Over Weight Loss Drug Sales

Danish pharmaceutical company Novo Nordisk has withdrawn its patent infringement case against telehealth service provider Hims & Hers, announcing instead a partnership that will bring the company’s weight management treatments to the digital health platform.

The settlement announcement triggered a dramatic surge in Hims & Hers Health Inc. stock prices, with shares jumping over 40% during Monday’s morning trading session.

The partnership agreement allows Hims to distribute both oral and injectable forms of widely-used GLP-1 medications, including the weight loss treatments Wegovy and diabetes drug Ozempic, through its online platform beginning this month.

As part of the settlement terms, Hims has agreed to discontinue all promotional activities for compounded versions of GLP-1 medications across its platform and marketing channels.

The legal dispute originated last month when Hims & Hers revealed intentions to introduce a lower-cost alternative to Wegovy, coinciding with Novo Nordisk’s launch of its reformulated flagship medication.

Novo Nordisk had threatened litigation at that time, characterizing the planned alternative as an unauthorized and unverified imitation of semaglutide, the primary component in Wegovy.

The telehealth company quickly abandoned its plans for the alternative product within 48 hours, following regulatory pressure from the Food and Drug Administration. The FDA had indicated it might limit access to ingredients required for producing compounded versions of these sought-after weight management medications.

Regulatory guidelines typically allow specialized pharmacies to create compounded alternatives to brand-name medications during supply shortages. The explosive popularity of GLP-1 treatments had previously attracted companies like Hims to enter this lucrative market sector, as many patients opted for out-of-pocket payments.

Although the FDA announced in 2024 that GLP-1 medications were no longer experiencing shortages—which should have limited compounding activities—companies such as Hims continued operations under provisions allowing customized patient formulations.

While reaching this settlement agreement, Novo Nordisk has maintained its option to reinitiate legal proceedings at a later date.